Goldman Sachs’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-226
| Closed | -$30K | – | 4856 |
|
|
2020
Q3 | $30K | Buy |
226
+174
| +335% | +$23.1K | ﹤0.01% | 4369 |
|
|
2020
Q2 | $9K | Sell |
52
-425
| -89% | -$73.6K | ﹤0.01% | 4332 |
|
|
2020
Q1 | $69K | Buy |
+477
| New | +$69K | ﹤0.01% | 4223 |
|
|
2019
Q2 | – | Sell |
-536
| Closed | -$327K | – | 4350 |
|
|
2019
Q1 | $327K | Buy |
536
+446
| +496% | +$272K | ﹤0.01% | 3709 |
|
|
2018
Q4 | $33K | Sell |
90
-192
| -68% | -$70.4K | ﹤0.01% | 4002 |
|
|
2018
Q3 | $190K | Sell |
282
-76
| -21% | -$51.2K | ﹤0.01% | 3833 |
|
|
2018
Q2 | $312K | Buy |
358
+55
| +18% | +$47.9K | ﹤0.01% | 3709 |
|
|
2018
Q1 | $381K | Sell |
303
-123
| -29% | -$155K | ﹤0.01% | 3611 |
|
|
2017
Q4 | $637K | Buy |
+426
| New | +$637K | ﹤0.01% | 3340 |
|